Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 3, 2016
Pharmacy Choice - News - U.S. Pharmaceutical Industry - December 3, 2016

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/3/16 - "Reticulocyte Growth Factor and Preparing Method and Application Thereof" in Patent Application Approval Process (USPTO 20160326226)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors JIN, YIFENG; WU, QI; ZHANG, TAIPING; MA, XIAOYAN; XUAN, JI, filed on January 27, 2014, was made available online on November 17, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent ap
12/3/16 - "Vegf Antagonist Compositions and Uses Thereof" in Patent Application Approval Process (USPTO 20160326501)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors Stefano, James; Pan, Clark; Qui, Huawei; O'Callaghan, Michael; Matthews, Gloria, filed on July 25, 2016, was made available online on November 17, 2016, according to news reporting originating from Washington, D.C., by NewsRx corresponden
12/3/16 - Cryoport Reports 38% Revenue Growth for the Second Quarter of Fiscal Year 2017
By a News Reporter-Staff News Editor at Investment Weekly News Cryoport, Inc., the world's leading cryogenic logistics company committed to providing innovative, reliable and efficient logistics solutions to the life sciences industry, announced financial results for the three and six-month periods ended September 30, 2016. "Revenues were up 38%
12/3/16 - CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week CSL Behring announced positive results from AEGIS-I, a Phase 2 b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I infusion therapy. Results from AEGIS-I were presented today at the American Heart Association Scientific Sessions in New Orleans
12/3/16 - Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Cumberland Pharmaceuticals, a U.S. specialty pharmaceutical company has entered into an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.' s innovative injectable methotrexate product line. Under the terms of the Agreement, Cumberland will be responsible for
12/2/16 - "Capsule Pharmaceutical Dosage Form Comprising a Suspension Formulation of an Indolinone Derivative" in Patent Application Approval Process (USPTO...
"Capsule Pharmaceutical Dosage Form Comprising a Suspension Formulation of an Indolinone Derivative" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors MESSERSCHMID, Roman; BINDER, Rudolf; BOCK, Thomas; BROX, Werner, filed on July 7, 2016, was made available online on No
12/2/16 - "Hypericin Albumin Nanoparticle-Escherichia Coli Serum Antibody Complex and Preparation Method and Application Thereof" in Patent Application...
"Hypericin Albumin Nanoparticle-Escherichia Coli Serum Antibody Complex and Preparation Method and Application Thereof" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors LIANG, JIANPING; GUO, WENZHU; HAO, BAOCHENG; TAO, LEI; LIU, YU; WANG, XUEHONG; SHANG, RUOFENG; GUO,
12/2/16 - "Optimized Pharmaceutical Formulation for the Treatment of Inflammatory Conditions of the Esophagus" in Patent Application Approval Process (USPTO...
"Optimized Pharmaceutical Formulation for the Treatment of Inflammatory Conditions of the Esophagus" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors GREINWALD, Roland; MUELLER, Ralph; PROELS, Markus; WILHELM, Rudolf, filed on December 18, 2014, was made available onli
12/2/16 - Advanced Medical Isotope Wins Default Judgment of $527,875.74
KENNEWICK, WA/ ACCESSWIRE/ December 2, 2016/ Advanced Medical Isotope Corporation, a late stage radiation oncology focused medical device company, announced today that it has been awarded in the Superior Court of the State of Washington in and for Benton County, a total judgment of...
12/2/16 - Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc., a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor, today announced the company granted a newly hired executive an option to purchase 130,000 shares of the company s common stock with a per share exercise price of $8.61,
12/2/16 - Akebia Therapeutics (AKBA) Buy Rating Reiterated with Higher Stock Price Target of $18
Akebia Therapeutics, Inc., a biopharma company that focuses on the development of innovative treatments for chronic kidney disease-related anemia, is maintaining its Buy rating, with a recommended stock price target of $18 compared to the current $8.90, according to an Aegis Capital Corp. report released on November 15. Both trials have been
12/2/16 - Allergan Announces Settlement of a DELZICOL (mesalamine) Patent Litigation
Allergan plc, a leading global pharmaceutical company, and its subsidiaries today announced that they, along with Qualicaps Co., Ltd., have reached a settlement regarding their litigation with Zydus Pharmaceuticals Inc., and Cadila Healthcare Limited relating to United States Patent No. 6,649,180 and Allergan's DELZICOL product. Allergan plc,.
12/2/16 - ALS Association Partnership to Fund RNS60 Treatment Trial with Biomarkers to Measure Neuroinflammation
The Amyotrophic Lateral Scloerosis Association issued the following news release:. The ALS Association, in partnership with ALS Finding a Cure and the Northeast ALS Consortium, is pleased to announce $1 million in funding to support a new ALS clinical trial to test the efficacy of the experimental drug RNS60 in reducing inflammation that may hasten
12/2/16 - AMA Supports Changing the Fundamentals of Drug Pricing
By a News Reporter-Staff News Editor at Insurance Weekly News Value-based pricing is a viable cost-saving solution for challenging the current rationale for determining what patients pay for prescription drugs in the U.S. market, according to policy adopted by physicians at the Interim Meeting of the American Medical Association. "The new AMA po
12/2/16 - Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab
Amgen and Allergan plc. today announced the submission of a Marketing Authorization Application to the European Medicines Agency for ABP 215, a biosimilar candidate to Avastin . "The submission of ABP 215 to the EMA is an important milestone as Amgen seeks to expand our oncology portfolio," said Sean E. Harper, M.D., executive vice president o
12/2/16 - Apellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNH
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim results from two ongoing Phase 1 b open-label, dose-escalation clinical trials of APL-2, a complement C3 inhibitor, in paroxysmal nocturnal hemoglobinuria. PNH is a rare, acquired, potential
12/2/16 - Arbutus Biopharma Corp. Files SEC Form 8-K, Current Report (Nov. 14, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on November 14, 2016. The SEC file number is 0001171843-16-013217.. A U.S. Securities and Exchange Commission filing is a for
12/2/16 - ARDM Out Of Orbit, CLSN To Report Data In Q1, MRK Seeks New Use For Old Drug
WHITEHOUSE STATION- Shares of Aradigm Corp. plunged over 56% on Thursday after two phase III studies evaluating Pulmaquin for the chronic treatment of Non-Cystic Fibrosis Bronchiectasis patients with lung infections with Pseudomonas aeruginosa delivered a mixed bag of results. The company will review the next steps towards an application for approv
12/2/16 - ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer
ARIAD Pharmaceuticals, Inc., a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the clinical data presented on brigatinib, the Company s investigational anaplastic lymphoma kinase inhibitor, at the International Association for the Study of Lung Cancer 17th World Conference on Lung Ca
12/2/16 - Australian Students School Martin Shkreli
Move over Bernie Sanders the drug industry has a new opponent now, and it s a group of high school kids. Australian students have successfully produced daraprim, the same drug Martin Shkreli deemed worth $750 a pop. Let s recap quickly: Martin Shkreli, then CEO of Turing Pharmaceuticals, generated a firestorm of controversy back in 2015, w
12/2/16 - AzurRx CEO Provides Shareholders With a "State of the Union" Communication [Cihan News Agency (Turkey)]
-AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the release of a Company overview as presented by AzurRx`s President& CEO, Thijs Spoor. Mr. Spoor began the communication by stating, "This Company overview serves to provide shareholders with a pe
12/2/16 - Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
Basel, Switzerland, December 02, 2016- Basilea Pharmaceutica Ltd. announced today the expansion of its ongoing oncology drug candidate BAL101553 clinical phase 1/ 2 a oral formulation study. Achim Kaufhold, Basilea's Chief Medical Officer, commented: "We are excited to explore BAL101553 in a separate glioblastoma study arm to our ongoing phase 1/
12/2/16 - BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies - Research and Markets
Research and Markets has announced the addition of the "BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies" report to their offering. BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies. This pdf report contains information about Bispecific Antibodies
12/2/16 - Benitec Biopharma Ltd Files SEC Form POS AM, Post-effective Amendments For Registration Statement (Nov. 15, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Benitec Biopharma Ltd was posted on November 15, 2016. The SEC file number is 0001193125-16-768290.. A U.S. Securities and Exchange Commission filing is a forma
12/2/16 - Best Biotech Stocks 2016: The NASDAQ's Top-Performers
The NASDAQ is known as the high tech hub so it s no surprise that so many biotechnology companies are listed here. It may not have the prestige of the New York Stock Exchange, but the NASDAQ is known as growth central where every year, select companies show massive gains.. Top-performing biotech stocks on the NASDAQ CoLucid Pharmaceuticals Ex
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415